TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06546969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 via intravenous infusion on days 1 and 8 of every 21-day cycle for up to 8 cycles. After the 16 weeks of trial participation, participants will continue chemoimmunotherapy per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/m2 via intravenous infusion on days 1 and 8 of every 21-day cycle for up to 8 cycles. After the 16 weeks of trial participation, participants will continue chemoimmunotherapy per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500mg via intravenous infusion on day 1 of every 21-day cycle for up to 8 cycles. After the 16 weeks of trial participation, participants will continue chemoimmunotherapy per standard of care.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Spatially Fractionated RT
Description: Administered to 1 measurable lesion on cycle 2-day 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Hyperthermia
Description: Deep hyperthermia alone will be delivered to the same lesion on cycle 3-day 1 and cycle 4-day 1
Study: NCT04284267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: TMS is a non-invasive tool for modulating patterns of brain activation and circuit connectivity. It uses electromagnetic pulses to induce electric currents over the cortex that serve to depolarize or hyperpolarize neurons, thereby changing patterns of synaptic activity. This study will use intermittent theta burst stimulation (iTBS), an efficient TMS protocol that uses high frequency (50Hz) triplets of TMS given every 200 milliseconds (i.e. at 5 Hz).
Study: NCT06424769

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Digital Care
Description: Participants will receive brief check-in surveys about their IBD symptoms once a month, via text messaging. If the survey response indicates significant symptoms, an alert will be sent to the participant's IBD care team and participant will receive more frequent surveys (weekly) over the next month. Participants and their IBD clinical team will be able to communicate by text for non-emergency IBD-related questions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Participants will receive education texts about IBD from trusted sources approximately twice a week. Topics will include: diet, medication adherence, fatigue, preventative care and other relevant issues.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education
Description: Participants will receive education texts about IBD from trusted sources approximately twice a week. Topics will include: diet, medication adherence, fatigue, preventative care and other relevant issues.
Study: NCT05372536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: parent-led home-administered low-dose Cytarabine
Description: Parents to the included participants are offered to administer the protocolized low-dose bolus (injection) Cytarabine in their children's CVCs at home. The administration procedure is developed as a simple and safe non-touch technique. The parents receive a video and paper-based guideline and information material followed by a 3-step nurse-led education program. The parents can administer the Cytarabine at home when they (and the child/adolescent) feel safe and comfortable managing the procedure and when the nurses are sure that the parents can manage the procedure at home. The first dose of Cytarabine is always administered at the hospital.
Study: NCT06395103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zilovertamab vedotin
Description: Administered via IV infusion
Study: NCT03905109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464
Description: ABX464 is a new anti-inflammatory drug. In the treatment arm, patients will receive dose A or Dose B of ABX464 orally once daily for 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464
Description: ABX464 is a new anti-inflammatory drug. In the treatment arm, patients will receive dose A or Dose B of ABX464 orally once daily for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the placebo group, patients will receive dose A or B ABX464-matching-placebo orally once daily for 52 weeks.
Study: NCT05596123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Chinese foot massage
Description: Participants in the TCFM group will receive six weekly 25-minute TCFM sessions by a therapist. Each session will start with an assessment of the legs and toes of the affected extremity for broken skin and lesions, which the therapist will try to avoid. The participant will be positioned with support to their foot and legs, with the sole directed downward and the therapist directly in alignment with the soles of the foot. The therapist will sequentially perform the following four steps for each TCFM session.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo massage
Description: The same therapist will give six weekly 25-minute placebo massage sessions to participants in the placebo massage group. These sessions will include assessing the affected extremity's legs and toes for lesions and broken skin in order to avoid them during the massage, as well as gentle foot and toe rubbing without any point stimulation or other TCFM techniques.
Study: NCT05508867

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: favezelimab/pembrolizumab
Description: Coformulated favezelimab/pembrolizumab (800 mg/200 mg), IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bendamustine
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: IV infusion
Study: NCT06696625

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0.1% sodium hyaluronate eye drop
Description: Participants received 0.1% sodium hyaluronate eye drop (HYLO COMOD® eye drops, Ursapharm, Ltd., Germany).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% sodium hyaluronate eye drop
Description: Participants received 0.1% sodium hyaluronate eye drop (HYLO COMOD® eye drops, Ursapharm, Ltd., Germany).
Study: NCT05198700

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Formulation
Description: Participants will be asked to take one sachet daily, containing 1 billion CFU of the probiotic formula. Sachets must be dissolved in warm water or mother's milk before consumption.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be asked to take one sachet containing the placebo daily. Sachets must be dissolved in warm water or mother's milk before consumption.
Study: NCT03595293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fNIRs-based Neurofeedback
Description: Patients receive fNIRs-based neurofeedback from the rDLPFC to allow them to modify activation within this area.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fNIRs-based Neurofeedback
Description: Patients receive fNIRs-based neurofeedback from the rDLPFC to allow them to modify activation within this area.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham feedback
Description: Patients receive fNIRs-based sham feedback from the left zygomatic area to allow them to modify activation within this area.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham feedback
Description: Patients receive fNIRs-based sham feedback from the left zygomatic area to allow them to modify activation within this area.
Study: NCT06697639

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation Group
Description: In addition to routine postpartum care, small-sized WAFF air cushions will be issued during the hospitalization period to guide patients in performing the WAFF pelvic-abdominal mechanical rehabilitation exercises. Patients will also be instructed to join the experimental group's WeChat group. After discharge, researchers will upload WAFF pelvic-abdominal mechanical rehabilitation instructional videos. Patients are required to complete their rehabilitation exercises twice daily, each session lasting 10-15 minutes. Patients need to upload their exercise videos twice a week, and researchers will provide motion guidance based on the video content until the patient's postpartum follow-up examination. The abdominal rectus muscle, pelvic floor muscle function, and adherence to rehabilitation exercises will be assessed for patients in both groups at 6-8 weeks and 6 months postpartum.
Study: NCT06698016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: Oral administration
Study: NCT04843852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]
Description: one 0.5ml intramuscular injection on day 0 and week 4.
Study: NCT06698016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Oral administration
Study: NCT05471700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subjects will receive Azacitidine 75 mg/m2 on days 1-7.Each course is 28 days long.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Subjects would receive Venetoclax once daily by oral. The doses of Venetoclax is 100 mg on Day 1, 200 mg on Day 2, reaching a target dose of 400 mg on Day 3 and continuing through Day 28. Each course is 28 days long.
Study: NCT04995796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys for Research Purposes
Description: VISIT #1:~1. Pre-Testing:~   * Pre Knowledge Test~  * Pre SURE (decisional conflict) test~2. Independent DSI/DA Interaction~3. Post-Testing:~   * Post Knowledge Test~  * Post SURE (decisional conflict) Test~  * Acceptability Index~  * Modified Single Item Literacy Screen~  * Additional Demographics~VISIT #2: Check-In Call 1 week later:~After viewing the DSI/DA and completing the post-test components above, the subjects will also complete a 5 minute debrief interview about 1 week later via phone or video conference with a team member to give feedback on their experience using the DSI/DA, including its strengths and weaknesses. This will allow for further improvement and refinement of the DSI.
Study: NCT05967455

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengue virus 1 Live Virus Human Challenge (DENV-1-LVHC)
Description: Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengue virus 1 Live Virus Human Challenge (DENV-1-LVHC)
Description: Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
Description: Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
Description: Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489
Study: NCT05682677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS
Description: iTBS over the left dorsolateral prefrontal cortex

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham iTBS
Description: sham iTBS over the left dorsolateral prefrontal cortex

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized, Augmented Cognitive Training (PACT)
Description: 6 sessions of PACT

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Personalized, Augmented Cognitive Training (PACT)
Description: 6 sessions of PACT
Study: NCT05956535

Intervention type: DEVICE
Intervention: Lotrafilcon A contact lenses
Description: CE-marked silicone hydrogel contact lenses

Intervention type: DEVICE
Intervention: Balafilcon A contact lenses
Description: CE-marked silicone hydrogel contact lenses
Study: NCT05900830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: play therapy
Description: A combined program based on physical and occupational therapy techniques within a play context

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: common educational methods
Description: the child will receive his education in a passive manner
Study: NCT03287583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT for Gambing
Description: The SBIRT intervention uses a brief gambling screening assessment to determine whether or not a participant is at risk for problem gambling. This is followed by a structured short brief intervention to assist people in better understanding their risk for gambling and what they can do to limit that risk.
Study: NCT06696976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: A qualified physiotherapist himself used the digital platform Zoom (Zoom Video Communications or WhatsApp video communication) to deliver synchronic online sessions (60 min each), sending each participant a link by email, half an hour before the weekly meetings. The patients were also invited to present themselves in comfortable gymnastic clothing and with tools useful for the motor program: a chair, a stick, a bottle full of water (or small weights if the patient had them), and a mat.~Nerve gliding exercises: These 5 Nerve gliding exercises will perform 3 times a week requiring 10 minutes to complete.~Balance exercises: Balance exercise include 10 exercises and take 20 minutes of completion, 2minute for each exercise.~Resistance training using Thera Band will performed with the presence of the researcher as an instructor.The main upper-extremity movements consisted of chest press, shoulder press etc and in lower extremity such as leg press ,back thgh press etc. in patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical rehabilitation
Description: A qualified physiotherapist himself used the digital platform Zoom (Zoom Video Communications or WhatsApp video communication) to deliver synchronic online sessions (60 min each), sending each participant a link by email, half an hour before the weekly meetings. The patients were also invited to present themselves in comfortable gymnastic clothing and with tools useful for the motor program: a chair, a stick, a bottle full of water (or small weights if the patient had them), and a mat.~Nerve gliding exercises: These 5 Nerve gliding exercises will perform 3 times a week requiring 10 minutes to complete.~Balance exercises: Balance exercise include 10 exercises and take 20 minutes of completion, 2minute for each exercise.~Resistance training using Thera Band will performed with the presence of the researcher as an instructor.The main upper-extremity movements consisted of chest press, shoulder press etc and in lower extremity such as leg press ,back thgh press etc. in patient.
Study: NCT06697587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Cognitive Reappraisal and Emotion Awareness Training (eCREAT)
Description: eCREAT features psychoeducational content on anger management, practical exercises, and homework assignments, all supported by an online therapist who provides text-based feedback. The protocol builds on a previously evaluated protocol for maladaptive anger (ClinicalTrials.gov; ID: NCT03858296) with added focus on anger inhibition.~eCREAT is based on the two-stage model of maladaptive anger inhibition (Burns et al., 2008), which posits that suppressed anger may rebound and return as angry fantasies and ruminations. To address these core mechanisms, the treatment includes training on adaptive anger processing and expression and strategies for disrupting anger ruminations. These added treatment components are based on established protocols for depressive rumination, and assertive expression of emotion, adapted for an anger context. Additionally, the treatment also focuses on how to flexibly shift between different emotion regulation strategies depending on contextual demands.
Study: NCT06698120

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Awake prone positioning (APP)
Description: * APP are realized following the diagnosis of ACS~* Prone positioning or supine positioning are performed under supervision of a physician or a nurse~* Maximum session duration: 16 hours per day~* Sessions of prone positioning can be shortened, if necessary (30 minutes minimum), for better tolerance~* Tolerance of prone positioning is assessed by the physician in charge and sessions and may be stopped in case of poor tolerance
Study: NCT06696222

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vegetarian yogurt
Description: Vegetarian yogurt alternative will be uesd.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ordinary diet with dairy based yogurt

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vegetarian meat alternative
Description: Vegetarian meat alternative consumed
Study: NCT03287583

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Control
Description: Participants randomized to the enhanced control condition will receive a handout with gambling resources.
Study: NCT06696222

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ordinary meat diet
Description: Ordinary meat diet used as placebo
Study: NCT06696586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl infusion
Description: will received lidocaine with dose 250 mg and fentanyl infusion in dose of 200 µg in rate 10ml /hr using 50ml syringe pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Injection
Description: will receive lidocaine 250 mg in addition to fentanyl injection in dose 100 µg by shots
Study: NCT05931588

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates excercises, streching and breathing
Description: international group receive Pilates exercises, stretching and breathing two times a week (30 min per session) perform 3 to 5 reps of Pilates exercises under supervision

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching and breathing
Description: control group guided with stretching and breathing home based program both group till 8 week both groups

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching and breathing
Description: control group guided with stretching and breathing home based program both group till 8 week both groups
Study: NCT05128773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amcenestrant
Description: tablet, oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: tablet, oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amcenestrant-matching placebo
Description: tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen-matching placebo
Description: tablet, oral
Study: NCT06364696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4396
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4396
Description: Intravenous (IV) infusion
Study: NCT05521724

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: resistance and strengthening exercises will be applied to a randomized patient group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: exercise
Description: resistance and strengthening exercises will be applied to a randomized patient group.
Study: NCT06403111

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy
Description: Participants will receive FMT combined with tislelizumab + pemetrexed + platinum-based treatment (lung adenocarcinoma) / albumin-bound paclitaxel + platinum-based treatment (lung squamous cell carcinoma) for 4-6 cycles. If there is no progression of the disease after 4-6 cycles of the first-line treatment, then patients will enter the maintenance treatment stage. Patients will receive tislelizumab maintenance treatment (lung squamous cell carcinoma), or tislelizumab + pemetrexed maintenance treatment (lung adenocarcinoma).
Study: NCT04935437

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised rehabilitation program.
Description: The program includes aerobic exercise, strengthening exercises, physiotherapy, psychological support and dietary advice.
Study: NCT06697275

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hypnotic Virtual reality
Description: Hypnotic Virtual reality mask Deepsen® with age-appropriate software Birdy®
Study: NCT05774977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aviation noise plus earplugs (AN+EP)
Description: The AN + EP night will consist of the aviation noise (AN) exposure with the addition of wearing earplugs overnight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aviation noise plus earplugs (AN+EP)
Description: The AN + EP night will consist of the aviation noise (AN) exposure with the addition of wearing earplugs overnight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aviation noise plus earplugs (AN+EP)
Description: The AN + EP night will consist of the aviation noise (AN) exposure with the addition of wearing earplugs overnight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aviation noise plus white noise 40 dBA (AN+BN40)
Description: The AN + BN40 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 40 dBA.
Study: NCT06536049

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT05774977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aviation noise plus white noise 40 dBA (AN+BN40)
Description: The AN + BN40 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 40 dBA.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aviation noise plus white noise 40 dBA (AN+BN40)
Description: The AN + BN40 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 40 dBA.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aviation noise plus white noise 40 dBA (AN+BN40)
Description: The AN + BN40 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 40 dBA.
Study: NCT06697275

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interactive virtual reality
Description: Interactive virtual reality mask Deepsen® with age-appropriate software Birdy®

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard method
Description: Use of local anesthesic cream + Nurse and/or parents distraction +/- anxioloytic gas
Study: NCT06698159

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoablation with cryoballoon 28 mm
Description: Pulmonary vein isolation using 28 mm balloon cryoablation